Jason Dinges is an investment professional and IP counsel at Morningside Technology Advisory LLC, where they focus on early-stage biotech venture capital investments aimed at developing innovative therapeutics. They have served as a board member for multiple companies, including CellCentric, Alentis Therapeutics, and Prilenia, among others, since 2011. Jason holds a Ph.D. from Iowa State University and a J.D. from the University of Iowa College of Law, complementing their extensive experience in the biotech field.
This person is not in the org chart
This person is not in any teams
This person is not in any offices